Jazz Pharmaceuticals completes Actio deal: what it means for Jazz Pharmaceuticals stock

Published on 10/05/2026 at 04:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 1.21 billion, up 16.00 percent year over year. For Jazz Pharmaceuticals stock, full-year guidance is USD 4.60 billion to USD 4.75 billion.

JAZZ, IE00B4Q5ZN47, Illustration mit AI erstellt.

Jazz Pharmaceuticals (ISIN IE00B4Q5ZN47) completed its acquisition of Actio Biosciences for USD 820.00 million upfront on September 15, 2026, according to Jazz Pharmaceuticals. The transaction adds ABS-1230, an experimental precision therapy for KCNT1-related epilepsy, to the company's rare-neurology pipeline.

Actio adds a rare epilepsy asset

Stock Titan reported that ABS-1230 holds Fast Track, Rare Pediatric Disease and Orphan Drug Product designations from the U.S. Food and Drug Administration. The deal also includes up to USD 500.00 million in contingent approval and sales milestones, giving Jazz a larger neurology opportunity while adding development risk before commercial revenue begins.

Revenue growth lifts 2026 guidance

Jazz reported record second-quarter 2026 revenue of USD 1.21 billion, up 16.00 percent from the same quarter of 2025, according to Stock Titan. GAAP net income was USD 192.80 million and GAAP diluted earnings per share were USD 2.78, while adjusted earnings per share reached USD 5.71.

The company raised full-year 2026 total revenue guidance to USD 4.60 billion to USD 4.75 billion from USD 4.25 billion to USD 4.50 billion. The range implies a higher revenue base than the earlier outlook, but the latest quarter also showed adjusted earnings per share of USD 5.71 below the USD 6.18 consensus cited by MarketBeat.

Nasdaq close and valuation

On Nasdaq, Jazz stock closed at USD 235.67 on October 2, 2026, at 4:00 p.m. EDT. The USD 128.80 to USD 266.38 52-week range places the close USD 30.71 below the high, a 11.53 percent gap calculated against the high.

MarketBeat reported on October 3, 2026, that Wall Street Zen downgraded Jazz from Strong Buy to Buy, while the broader analyst tally included 18 Buy ratings, one Strong Buy rating and one Hold rating. The report also cited a consensus price target of USD 291.15, which stands USD 55.48 above the Nasdaq close.

Jazz Pharmaceuticals stock was last represented by a prior close of EUR 209.40 at Lang & Schwarz for October 2, 2026. The primary Nasdaq reference was USD 235.67 at the October 2 close, while market capitalization was USD 14.8 billion on that date.